Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inactive phospholipase C-like protein 1 (PLCL1) is a member of the phospholipase C family that, unlike other family members, lacks catalytic phospholipase activity due to changes in its active site. It is involved in inositol phospholipid-based intracellular signaling cascades and acts as a regulatory protein rather than an enzyme. PLCL1 is implicated in the regulation of GABA A receptor endocytosis, contributing to synaptic inhibition in the nervous system, and functions as an inhibitor of protein phosphatase 1 catalytic subunit (PPP1C). In immune contexts, PLCL1 participates in inflammation regulation, particularly through the modulation of NLRP3 inflammasome activity in rheumatoid arthritis fibroblast-like synoviocytes. Aberrant expression of PLCL1 has been linked to cancer progression, especially in lung carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inactive phospholipase C-like protein 1 (PLCL1).